Exp Clin Endocrinol Diabetes 2010; 118(6): 356-359
DOI: 10.1055/s-0029-1243603
Mini Review

© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Insulin Signal Transduction in Normal Cells and its Role in Carcinogenesis

K. Müssig1 , H.-U. Häring1
  • 1Division of Endocrinology, Diabetology, Angiology, Nephrology, and Clinical Chemistry, Department of Internal Medicine, University Hospital of Tübingen, Tübingen, Germany
Further Information

Publication History

received 17.11.2009 first decision 17.11.2009

accepted 20.11.2009

Publication Date:
05 February 2010 (online)

Abstract

Convincing epidemiological evidence exists for a causal relationship between increased risk of cancer development and progression and type 2 diabetes mellitus as well as obesity. Though the underlying mechanisms remain elusive, in light of the well-described mitogenic actions of insulin, hyperinsulinaemia in the presence of insulin resistance is probably a key factor. In this short review, an overview over the insulin signalling cascade is given paying special attention to the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI 3-K)/mammalian target of rapamycin (mTOR) pathways which are involved in protein synthesis and cell growth.

References

  • 1 Adjei AA, Cohen RB, Franklin W. et al . Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.  J Clin Oncol. 2008;  26 2139-2146
  • 2 Alessi DR, James SR, Downes CP. et al . Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha.  Curr Biol. 1997;  7 261-269
  • 3 Baltensperger K, Kozma LM, Cherniack AD. et al . Binding of the Ras activator son of sevenless to insulin receptor substrate-1 signaling complexes.  Science. 1993;  260 1950-1952
  • 4 Burgering BM. A brief introduction to FOXOlogy.  Oncogene. 2008;  27 2258-2262
  • 5 Calle EE, Rodriguez C, Walker-Thurmond K. et al . Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.  S. adults. N Engl J Med. 2003;  348 1625-1638
  • 6 Cheatham B, Kahn CR. Insulin action and the insulin signaling network.  Endocr Rev. 1995;  16 117-142
  • 7 Coughlin SS, Calle EE, Teras LR. et al . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.  Am J Epidemiol. 2004;  159 1160-1167
  • 8 Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis.  Lancet. 2008;  372 657-668
  • 9 Cusi K, Maezono K, Osman A. et al . Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.  J Clin Invest. 2000;  105 311-320
  • 10 Davies H, Bignell GR, Cox C. et al . Mutations of the BRAF gene in human cancer.  Nature. 2002;  417 949-954
  • 11 Draznin B. Mitogenic action of insulin: friend, foe or ‘frenemy’?.  Diabetologia. 2009; 
  • 12 Garcia-Martinez JM, Alessi DR. mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1).  Biochem J. 2008;  416 375-385
  • 13 Han SW, Kim TY, Jeon YK. et al . Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.  Clin Cancer Res. 2006;  12 2538-2544
  • 14 Hersey P, Bastholt L, Chiarion-Sileni V. et al . Small molecules and targeted therapies in distant metastatic disease.  Ann Oncol. 2009;  20 ((Suppl 6)) vi35-vi40
  • 15 Hess G, Herbrecht R, Romaguera J. et al . Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.  J Clin Oncol. 2009;  27 3822-3829
  • 16 Hong DS, Sebti SM, Newman RA. et al . Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies.  Clin Cancer Res. 2009; 
  • 17 Hooper, C. Insulin signaling pathways. htpp://www.abcam.com/index.html?pageconfig=resource&idref=10602&pid=7 abcam Inc., Cambridge, MA, USA 23-5-2009
  • 18 Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth.  Biochem J. 2008;  412 179-190
  • 19 Hudes G, Carducci M, Tomczak P. et al . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.  N Engl J Med. 2007;  356 2271-2281
  • 20 Jonasch E, Corn P, Pagliaro LC. et al . Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.  Cancer. 2009; 
  • 21 Kasuga M, Karlsson FA, Kahn CR. Insulin stimulates the phosphorylation of the 95 000-dalton subunit of its own receptor.  Science. 1982;  215 185-187
  • 22 Kim J, Reber HA, Dry SM. et al . Unfavourable prognosis associated with K-ras gene mutation in pancreatic cancer surgical margins.  Gut. 2006;  55 1598-1605
  • 23 Lancet JE, Gojo I, Gotlib J. et al . A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.  Blood. 2007;  109 1387-1394
  • 24 Montagut C, Settleman J. Targeting the RAF-MEK-ERK pathway in cancer therapy.  Cancer Lett. 2009;  283 125-134
  • 25 Myers Jr MG, White MF. The new elements of insulin signaling. Insulin receptor substrate-1 and proteins with SH2 domains.  Diabetes. 1993;  42 643-650
  • 26 Neubauer A, Maharry K, Mrozek K. et al . Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.  J Clin Oncol. 2008;  26 4603-4609
  • 27 Pao W, Wang TY, Riely GJ. et al . KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.  PLoS Med. 2005;  2 e17
  • 28 Pilarski R. Cowden syndrome: a critical review of the clinical literature.  J Genet Couns. 2009;  18 13-27
  • 29 Rinehart J, Adjei AA, Lorusso PM. et al . Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.  J Clin Oncol. 2004;  22 4456-4462
  • 30 Rushworth LK, Hindley AD, O'Neill E. et al . Regulation and role of Raf-1/B-Raf heterodimerization.  Mol Cell Biol. 2006;  26 2262-2272
  • 31 Sarbassov DD, Guertin DA, Ali SM. et al . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.  Science. 2005;  307 1098-1101
  • 32 Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth.  Nature. 2006;  441 424-430
  • 33 Shepherd PR, Withers DJ, Siddle K. Phosphoinositide 3-kinase: the key switch mechanism in insulin signalling.  Biochem J. 1998;  333 471-490
  • 34 Skolnik EY, Batzer A, Li N. et al . The function of GRB2 in linking the insulin receptor to Ras signaling pathways.  Science. 1993;  260 1953-1955
  • 35 Stephens L, Anderson K, Stokoe D. et al . Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B.  Science. 1998;  279 710-714
  • 36 Tsai J, Lee JT, Wang W. et al . Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.  Proc Natl Acad Sci USA. 2008;  105 3041-3046
  • 37 Ullrich A, Bell JR, Chen EY. et al . Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.  Nature. 1985;  313 756-761
  • 38 Virkamaki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.  J Clin Invest. 1999;  103 931-943
  • 39 Vitale A, Volk ML, Pastorelli D. et al . Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: A cost-benefit analysis while awaiting data on sorafenib safety.  Hepatology. 2009; 
  • 40 Wang X, Jiang X. Post-translational regulation of PTEN.  Oncogene. 2008;  27 5454-5463
  • 41 Watson RT, Shigematsu S, Chiang SH. et al . Lipid raft microdomain compartmentalization of TC10 is required for insulin signaling and GLUT4 translocation.  J Cell Biol. 2001;  154 829-840
  • 42 Zhang J, Gao Z, Yin J. et al . S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2.  J Biol Chem. 2008;  283 35375-35382
  • 43 Zhu K, Hamilton AD, Sebti SM. Farnesyltransferase inhibitors as anticancer agents: current status.  Curr Opin Investig Drugs. 2003;  4 1428-1435

Correspondence

Prof. Dr. med. H.-U. Häring

Medizinische Klinik IV

Universitätsklinikum

Tübingen

Otfried-Müller-Str 10

D-72076 Tübingen

Germany

Phone: +49/7071/2982735

Fax: +49/7071/292784

Email: hans-ulrich.haering@med.uni-tuebingen.de

    >